Kraus, Inga

[["dc.bibliographiccitation.firstpage","691"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Alzheimer's Disease"],["dc.bibliographiccitation.lastpage","705"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Klafki, Hans-Wolfgang"],["dc.contributor.author","Hafermann, Henning"],["dc.contributor.author","Bauer, Chris"],["dc.contributor.author","Haußmann, Ute"],["dc.contributor.author","Kraus, Inga"],["dc.contributor.author","Schuchhardt, Johannes"],["dc.contributor.author","Muck, Stephan"],["dc.contributor.author","Scherbaum, Norbert"],["dc.contributor.author","Wiltfang, Jens"],["dc.date.accessioned","2017-09-07T11:44:28Z"],["dc.date.available","2017-09-07T11:44:28Z"],["dc.date.issued","2016"],["dc.description.abstract","A comprehensive assay validation campaign of a commercially available chemiluminescence multiplex immunoassay for the simultaneous measurement of the amyloid-β peptides Aβ38, Aβ40, and Aβ42 in human cerebrospinal fluid (CSF) is presented. The assay quality parameters we addressed included impact of sample dilution, parallelism, lower limits of detection, lower limits of quantification, intra- and inter-assay repeatability, analytical spike recoveries, and between laboratory reproducibility of the measurements. The assay performed well in our hands and fulfilled a number of predefined acceptance criteria. The CSF levels of Aβ40 and Aβ42 determined in a clinical cohort (n = 203) were statistically significantly correlated with available ELISA data of Aβ1–40 (n = 158) and Aβ1–42 (n = 179) from a different laboratory. However, Bland-Altman method comparison indicated systematic differences between the assays. The data presented here furthermore indicate that the CSF concentration of Aβ40 can surrogate total CSF Aβ and support the hypothesis that the Aβ42/Aβ40 ratio outperforms CSF Aβ42 alone as a biomarker for Alzheimer’s disease due to a normalization to total Aβ levels."],["dc.identifier.doi","10.3233/jad-160398"],["dc.identifier.gro","3151666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8483"],["dc.language.iso","en"],["dc.notes.status","public"],["dc.notes.submitter","chake"],["dc.relation.issn","1387-2877"],["dc.title","Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","691"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Alzheimer s Disease"],["dc.bibliographiccitation.lastpage","705"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Klafki, Hans-W."],["dc.contributor.author","Hafermann, Henning"],["dc.contributor.author","Bauer, Christian R."],["dc.contributor.author","Haussmann, Ute"],["dc.contributor.author","Kraus, Inga"],["dc.contributor.author","Schuchhardt, Johannes"],["dc.contributor.author","Muck, Stephan"],["dc.contributor.author","Scherbaum, Norbert"],["dc.contributor.author","Wiltfang, Jens"],["dc.date.accessioned","2018-11-07T10:19:59Z"],["dc.date.available","2018-11-07T10:19:59Z"],["dc.date.issued","2016"],["dc.description.abstract","Acomprehensive assay validation campaign of a commercially available chemiluminescence multiplex immunoassay for the simultaneous measurement of the amyloid-beta peptides A beta(38), A beta(40), and A beta(42) in human cerebrospinal fluid (CSF) is presented. The assay quality parameters we addressed included impact of sample dilution, parallelism, lower limits of detection, lower limits of quantification, intra- and inter-assay repeatability, analytical spike recoveries, and between laboratory reproducibility of the measurements. The assay performed well in our hands and fulfilled a number of predefined acceptance criteria. The CSF levels of A beta(40) and A beta(42) determined in a clinical cohort (n = 203) were statistically significantly correlated with available ELISA data of A beta(1-40) (n = 158) and A beta(1-42) (n = 179) from a different laboratory. However, Bland-Altman method comparison indicated systematic differences between the assays. The data presented here furthermore indicate that the CSF concentration of A beta(40) can surrogate total CSF A beta and support the hypothesis that the A beta(42)/A beta(40) ratio outperforms CSF A beta(42) alone as a biomarker for Alzheimer's disease due to a normalization to total A beta levels."],["dc.identifier.doi","10.3233/JAD-160398"],["dc.identifier.isi","000384087200023"],["dc.identifier.pmid","27567847"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41786"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ios Press"],["dc.relation.issn","1875-8908"],["dc.relation.issn","1387-2877"],["dc.title","Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-beta Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1219"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Structure"],["dc.bibliographiccitation.lastpage","1226"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Rudolph, M."],["dc.contributor.author","Kraus, I."],["dc.contributor.author","Dickmanns, Achim"],["dc.contributor.author","Eickmann, M."],["dc.contributor.author","Garten, W."],["dc.contributor.author","Ficner, R."],["dc.date.accessioned","2017-09-07T11:44:16Z"],["dc.date.available","2017-09-07T11:44:16Z"],["dc.date.issued","2003"],["dc.description.abstract","Borna disease virus (BDV) causes an infection of the central nervous system in a wide range of vertebrates, which can fatally progress to an immune-mediated disease, called Borna disease. BDV is a member of the Mononegavirales, which also includes the highly infectious measles and Ebola viruses. The viral nucleo-proteins are central to transcription, replication, and packaging of the RNA genome. We present the X-ray structure of the BDV nucleoprotein determined at 1.76 Angstrom resolution. The structure reveals a novel fold, organized into two distinct domains, and an assembly into a planar homotetramer. Surface potential calculations strongly support an RNA binding model with the RNA wrapping around the outside of the tetramer, although a positively charged central channel in the tetramer could fit single-stranded RNA in an alternative binding mode. This first structure of an RNA virus nucleoprotein provides a paradigmatic model for RNA packaging and replication of single-stranded RNA viruses."],["dc.identifier.doi","10.1016/j.str.2003.08.011"],["dc.identifier.gro","3144057"],["dc.identifier.isi","000185758500009"],["dc.identifier.pmid","14527390"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1639"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0969-2126"],["dc.title","Crystal structure of the Borna disease virus nucleoprotein"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]